An observational study in AI (Artificial Intelligence), Mammary Cancer and Lung Cancer, sponsored by Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-26.
Sponsored by Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies in Breast Neoplasms with a site in Russian Federation — 9 open to participants now, 10 under way, 1 of them phase 3. Breast Neoplasms · Russian Federation.
Among the 180 studies in Breast Neoplasms with a site in Russian Federation, this one has the largest planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2020, is one of 13 observational ones, and was the 161st registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →9 of the 180 studies in Breast Neoplasms with a site in Russian Federation are open now. Recruiting first, the newest first:
I.M. Sechenov First Moscow State Medical University · Sites in Russian Federation
Ages 18–70 · Women only
N.N. Petrov National Medical Research Center of Oncology · Sites in Russian Federation
Ages 18+ · Women only
Moscow Clinical Scientific Center · Sites in Russian Federation
Ages 18–80
Moscow Clinical Scientific Center · Sites in Russian Federation
Ages 45–74 · Women only
Branch Office of "Hadassah Medical Ltd" · Sites in Russian Federation
Ages 18+ · Women only
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 60 · Phase 3 94
First in 1996; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 133,000 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 334 across the 166 interventional studies, 300 across the 13 observational. Of the 154 that completed or were terminated, 121 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
158 of 180 have an industry lead sponsor. The 10 most frequent:
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department is the lead sponsor of 11 studies on the registry; 5 are open to participants now.
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 180 studies in Breast Neoplasms with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
It is planned to integrate various services based on computer vision technologies for analysis of the certain type of x-ray study into Moscow Unified Radiological Information Service (hereinafter referred to as URIS).
As a result of using computer vision-based services, it is expected:
Recently a growth in the number of radiology studies across multiple modalities has been observed alongside the modest increase in staffing levels. This carries higher risks of increased workload and efficiency losses. The integration of computer vision-based services into URIS will improve the radiologists' productivity and job performance.
Existing prerequisites for conducting the study:
Study objectives:
METHODOLOGY
1)Detection of CT signs consistent with COVID-19 (coronavirus) lung involvement (Chest CT); 2) Emphysema extent (Chest CT); 3) Detection of CT signs consistent with malignant neoplasm in the lungs (Chest CT); 4) Detection of LDCT signs consistent with malignant neoplasm in the lungs (Chest LDCT); 5) Detection and localization of compression vertebral fractures with a degree of vertebral body deformity of over 25% according to the Genant semi-quantitative scale, grades 2-3 (Chest CT); 6) Detection of free pleural fluid (effusion) (Chest CT); 7) Detection of enlarged intrathoracic lymph nodes (lymphadenopathy) (Chest CT); 8) Detection of bronchiectasis (Chest CT); 9) Detection of CT signs consistent with pulmonary tuberculosis (Chest CT); 10) Coronary calcium score (Chest CT/ LDCT); 11) Paricardial fat volume (Chest CT); 12) Dilation of ascending and descending thoracic aortas (Chest CT/ LDCT); 13) Dilation of the pulmonary trunk (Chest CT/ LDCT); 14) Detection of sarcoidosis (Chest CT); 15) Detection of signs consistent with the impairment of lung airness (Chest CT); 16) Detection of signs consistent with the focal lesions in the chest bones (Chest CT); 17) Detection of CT signs consistent with rib fracture (Chest CT); 18) Detection of signs of urolithiasis (Abdominal CT); 19) Detection of signs consistent with the focal lesions in the skeleton bones (Abdominal CT); 20) Detection of liver lesions (Abdominal CT); 21) Detection of CT signs consistent with gallbladder stones (Abdominal CT); 22) Detection of CT signs consistent with renal lesions (Abdominal CT); 23) Measuring the abdominal aorta dilation (Abdominal CT); 24) Detection of adrenal lesions (Abdominal/Chest CT); 25) Detection and localization of compression vertebral fractures with a degree of vertebral body deformity of over 25% according to the Genant semi-quantitative scale, grades 2-3 (Abdominal CT); 26) Automation of routine liver measurements (dimensions, liver density, choledochus diameter, portal vein diameter) (Abdominal CT); 27) Automation of routine kidney measurements (kidney size, pelvicalyceal system size) (Abdominal CT); 28) Automation of routine measurements of spleen and pancreas (size, density of the spleen and pancreas) (Abdominal CT); 29) Detection of acute ischemic stroke and its ASPECTS score (Head CT); 30) Detection of hemorrhage and its automatic volume calculation in ml or cm³ (Head CT); 31) Automation of routine measurements (ventriculometry, displacement of median structures, measurement of the craniovertebral junction) (Head CT); 32) Detection and localization of (at least 7) signs consistent with the priority disease (Chest XR); 33) Detection of signs (at least one) consistent with bone fracture (MSS XR); 34) Detection of radiologic signs (at least one) consistent with arthrosis of the joints (MSS XR); 35) Detection of radiological signs (at least one) consistent with deforming arthrosis of the hip (MSS XR); 36) Detection of radiological signs (at least one) consistent with the fracture of the shoulder joint bones (MSS XR); 37) Detection of radiological signs (at least one) consistent with the fracture of the hip joint bones (MSS XR) 38) Detection of radiological signs (at least one) consistent with the fracture of the ankle joint bones (MSS XR).
During the Experiment, a radiologist will routinely be able to:
Systematization and final analysis of the Experiment results is carried out within three months from the completion date of the last Service participation in the Experiment.
Based on the results of the Experiment, recommendations can be prepared on the possibility to register certain services as a medical device (software).
patients over the age of 18 attending outpatient clinics
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The experiment is conducted on 10 types of studies with AI: 1. Chest CT/ LDCT with different pathologies; 2. Abdominal CT with different pathologies; 3. Head CT with different pathologies; 4. MSS XR with different fractures 5. Spine XR with different pathologies; 6. MMG; 7. Brain MRI with different pathologies; 8. Cervical spine MRI, Lumbosacral spine MR and Thoracic spine MRI with spine pathologies 9. Knee joint MRI 10. Lesser pelvis MRI.
The experiment is conducted on 10 types of studies without AI: 1. Chest CT/ LDCT with different pathologies; 2. Abdominal CT with different pathologies; 3. Head CT with different pathologies; 4. MSS XR with different fractures 5. Spine XR with different pathologies; 6. MMG; 7. Brain MRI with different pathologies; 8. Cervical spine MRI, Lumbosacral spine MR and Thoracic spine MRI with spine pathologies 9. Knee joint MRI 10. Lesser pelvis MRI.
Number of errors
Change of at least 30% in the number of errors in interpretation of the studies with using computer vision-based services compared to the number of errors in interpretation without their application.
Time frame: Upon completion, up to 4 years
Report turnaround time
Change of at least 30% of the time from the study completion to report finalization by a radiologist.
Time frame: Upon completion, up to 3 year
Number of reports
Change of at least 30% in the number of radiology reports provided by a radiologist per shift.
Time frame: Upon completion, up to 4 years
Change in the errors of services per the feedback form
Change of at least 30% in computer vision-based services errors as per integrated feedback form for radiologists in the PACS. Types of errors: 1. Technological defect (absent AI-generated series, partially generated AI series, DICOM SR and images mismatch, multiple conflicting results) 2. Major discrepancy (findings outside the region of interest, irrelevant findings) 3. Inaccurate diagnosis 4. Inaccurate lesion localisation 5. Inaccurate lesion classification 6. Other (free-text field)
Time frame: Upon completion, up to 4 years
Plan to share: No
Started Feb 2020 (actual). Primary completion is estimated for Jan 2024, 46 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 46 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department